Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SUVN-D1044
- Development stage
- Unknown
- Lead developer
- Suven Life Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SUVN-D1044 is a small molecule, non-brain penetrant 5-HT4 receptor agonist being developed by Suven Life Sciences for the treatment of gastrointestinal disorders. By selectively targeting 5-HT4 receptors in the periphery, the drug aims to enhance gastrointestinal motility and secretion without inducing central nervous system-related side effects. Following a successful pre-IND meeting with the FDA, the compound was slated to enter Phase 1 clinical trials in late 2023. Preliminary assessments, including in-vitro studies, pharmacokinetics, and safety profiles, have been completed to support its clinical advancement.
02
Targets
HTR4 (5-Hydroxytryptamine receptor 4)
Beyond the preview
Go deeper on SUVN-D1044.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SUVN-D1044.